Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
Feature|Videos|April 29, 2024
Alcami: Beyond Expectations
Bill Humphries (CEO, Alcami) dives into an overview of Alcami's capabilities and how they value their client's innovations.
Advertisement
Bill Humphries sat down with Pharmaceutical Technology to highlight the importance of working with Alcami. Learn more about:
- How Alcami stays ahead of the curve and makes the smart investments in capacity and technology to meet market demand and address sector challenges.
- Understand Alcami's position to support the future of pharma and biotech, ready with innovative solutions and strategic partnerships that streamline and optimize the path to patients for clients’ therapeutics.
- Whether clients tap Alcami for one service or seek the benefit of a seamless end-to-end solution, the company’s Lab Services, Drug Product Manufacturing, and Pharma Storage and Services are fully integrated and optimized.
Advertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
4
PharmTech’s Weekly Roundup—September 25, 2026
5